Abstract Library

#2900 Radionuclide Therapy in the Continuum of Care of Neuroendocrine Tumors: Results of the SEPTRALU Study

Introduction: Peptide receptor radionuclide therapy (PRRT, Lu-177-DOTATATE) is safe and effective in neuroendocrine tumors (NET). However, the best sequence of administration is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Mitjavila Casanovas M, Carmona-Bayonas A, Pubul V, García-Cañamaque L, Aller J,

Keywords: Lu-177-DOTATATE, radionuclide, survival, treatment,

#2888 Progression-Free Survival as a Surrogate Endpoint in Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues

Introduction: Progression-free survival (PFS) has been used as surrogate endpoint in phase III trials with somatostatin analogues for gastroentero-pancreatic neuroendocrine tumors (GEP-NET). However, this endpoint has not been validated in this scenario.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Jimenez Fonseca P

Authors: Jimenez-Fonseca P, Carmona-Bayonas A, Lamarca A, Barriuso J, Castaño A,

Keywords: somatostatin analogues, surrogate, PFS, OS, correlation, kendall,

#2883 Comparison of Somatostatin Analogues in Metastatic Gastroenteropancreatic Neuroendocrine Tumors from a Bayesian Perspective: The GETNE-TRASGU Study

Introduction: Somatostatin analogues (SSA), octreotide LAR (Oct) and lanreotide autogel (Lan), significantly prolong progression-free survival (PFS) in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, comparative data are not available and randomized trials comparing both SSAs are unlikely to be conducted.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Carmona-Bayonas A, Jimenez-Fonseca P, Lamarca A, Barriuso J, Castaño A,

Keywords: Bayesian model, octreotide, lanreotide, progression-free survival, efficacy,

#2880 177-Lu-DOTATATE in 200 Patients with Neuroendocrine Tumors: Real-World Data from the SEPTRALU Registry

Introduction: Patients with neuroendocrine tumors have few treatment options after progression to first-line somatostatin analogues.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carmona Bayonas A

Authors: Carmona-Bayonas A, Mitjavila Casanovas M, Belló P, Percovich J, Prieto A,

Keywords: PRRT, 177Lu-DOTATATE, radionuclide,

#2299 Expanding the WHO 2017 Classification to Gastrointestinal Tumors: Real-World Data from the R-GETNE Registry

Introduction: The update of the WHO 2017 classification of pancreatic neuroendocrine tumors (NETs) introduces the distinction between NET & NEC G3, based on histological differentiation. However, little is known about the possibility of extending this concept to non-pancreatic NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Carmona-Bayonas A, Jimenez-Fonseca P, Castaño A, Capdevila J, Benavent M,

Keywords: WHO classification, NET G3, NEC G3, non-pancreatic NET, poorly differentiated,